Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$123.19 USD
-1.40 (-1.12%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $123.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Ascendis Pharma A/S (ASND) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$182.25 | $262.00 | $140.00 | 47.94% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Ascendis Pharma A/S comes to $182.25. The forecasts range from a low of $140.00 to a high of $262.00. The average price target represents an increase of 47.94% from the last closing price of $123.19.
Analyst Price Targets (12)
Broker Rating
Ascendis Pharma A/S currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.46 a month ago based on 13 recommendations.
Of the 14 recommendations deriving the current ABR, 11 are Strong Buy, representing 78.57% of all recommendations. A month ago, Strong Buy represented 76.92%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.46 | 1.46 | 1.46 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/3/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
4/1/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Hold | Hold |
3/29/2024 | Goldman Sachs | Paul K Choi | Strong Buy | Strong Buy |
3/15/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
2/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/8/2024 | Wedbush Securities | Andreas Argyrides | Strong Buy | Strong Buy |
2/8/2024 | Not Identified | Not Identified | Hold | Hold |
8/16/2023 | Berenberg Bank | Caroline H Palomeque | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 14 |
Average Target Price | $182.25 |
LT Growth Rate | 35.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | -1.46 |